EverSource Wealth Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

EverSource Wealth Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.43K	Buy	1,944 +245	+14%	+$978	﹤0.01%	2944
2026 Q1	$3.98K	Buy	1,699 +55	+3%	+$142	﹤0.01%	3364
2025 Q4	$2.22K	Sell	1,644 -949	-37%	-$1.38K	﹤0.01%	3467
2025 Q3	$3.92K	Buy	2,593 +243	+10%	+$364	﹤0.01%	3260
2025 Q2	$2.73K	Sell	2,350 -127	-5%	-$168	﹤0.01%	3393
2025 Q1	$3.94K	Sell	2,477 -879	-26%	-$1.9K	﹤0.01%	2614
2024 Q4	$10.2K	Buy	3,356 +87	+3%	+$285	﹤0.01%	1986
2024 Q3	$12K	Buy	3,269 +472	+17%	+$1.72K	﹤0.01%	1757
2024 Q2	$10.9K	Buy	2,797 +1,187	+74%	+$13.3K	﹤0.01%	1806
2024 Q1	$17.8K	Buy	1,610 +565	+54%	+$7.77K	﹤0.01%	1418
2023 Q4	$15.8K	Buy	1,045 +904	+641%	+$13.2K	﹤0.01%	1346
2023 Q3	$2.83K	Hold	141	–	–	﹤0.01%	1903
2023 Q2	$3.98K	Buy	+141	New	+$3.38K	﹤0.01%	1822

Other funds holding ZNTL

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SCP

Sivia Capital Partners Mill Valley, California $822M AUM 48.82% 1-Year Est. Return

ECM

Evergreen Capital Management Bellevue, Washington $5.7B AUM 32.06% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

EverSource Wealth Advisors's ZNTL Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Zentalis Pharmaceuticals (ZNTL) stake by 14% in Q2 2026, buying an estimated $978 and bringing the position to 1,944 shares worth $9.43K. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

EverSource Wealth Advisors first reported a position in ZNTL in Q2 2023 and has held it in 13 quarters since. The position peaked at $17.8K in Q1 2024. 20 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

EverSource Wealth Advisors held 1,944 shares of Zentalis Pharmaceuticals worth $9.43K as of Q2 2026.
EverSource Wealth Advisors bought 245 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $978.
Zentalis Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2944 holding.
EverSource Wealth Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
EverSource Wealth Advisors's Zentalis Pharmaceuticals position peaked at $17.8K in Q1 2024.
20 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.